Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope.  Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer.  The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. 

Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products.  For more information please visit www.macrocyclics.com.

Health Care

Nuclear

Orano Med

Julien Dodet

Virgil Dodson

Sadaf Qureshi

Michael Courtney

Haley Lozano-Sprague

Carter Rose

Allison Manuel

Julien Torgue

Nicolas Bozovic

Gwenaelle Nourry

Pascal Mirocha

J. Robert Chastain (Rob)

The Research & Development team at Orano Med is dedicated to advancing the field of nuclear medicine by developing high-purity lead-212 (Pb-212) production processes for targeted alpha therapy (TAT). This team conducts cutting-edge research to create innovative cancer treatments that precisely target and destroy cancer cells while minimizing damage to healthy tissues. Through collaboration, they also focus on peptide drug discovery and the development of radiopharmaceuticals, ensuring comprehensive support from initial research to clinical trials.

Research & Development

Production and Operations

Quality Assurance and Control Team

Engineering and Technical Team

Research & Development

About

Team members

Other teams at Orano Med

Production and Operations

Quality Assurance and Control Team

Engineering and Technical Team